US7304084B2ExpiredUtilityPatentIndex 43

6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt

Assignee: UNIV NEBRASKAPriority: Feb 20, 2003Filed: Jan 17, 2006Granted: Dec 4, 2007

Est. expiryFeb 20, 2023(expired)· nominal 20-yr term from priority

Inventors:RANDALL JARED LYNN GIBBS RICHARD ALAN BOSCH GREGORY KENT CURTIS MICHAEL DAVID SUN LI NIKOLAIDES NICHOLAS

C07D 235/06

PatentIndex Score

Cited by

References

Claims

Abstract

6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile, and the anhydrous monoacetate salt thereof, are useful in the treatment of alpha-2 mediated disorders such as ocular hypertension.

Claims

exact text as granted — not AI-modified

1. A composition comprising 6-[(4,5-dihydro-IH-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile, substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile, or tautomer thereof. 
     
     
       2. The composition of  claim 1 , wherein the concentration of 2,3,7-triamino-4,6-dimethyl-1,9-phenazine-dicarbonitrile is less than 70 parts per billion. 
     
     
       3. The composition of  claim 2 , wherein the concentration of 2,3,7-triamino-4,6-dimethyl-1,9-phenazine-dicarbonitrile is less than 5 parts per billion. 
     
     
       4. The composition of  claim 1  in the form of anhydrous monoacetate salt.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.